Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Effekt och biverkningar av adalimumab vid behandling av ankyloserande spondylit
Linnaeus University, Faculty of Health and Life Sciences, Department of Chemistry and Biomedical Sciences.
2019 (Swedish)Independent thesis Basic level (degree of Bachelor), 10 credits / 15 HE creditsStudent thesisAlternative title
Effect and side effects of adalimumab in the treatment of ankylosing spondylitis (English)
Abstract [sv]

Ankyloserande spondylit (AS) är en kronisk inflammatorisk sjukdom som drabbar axialskelettet. Inflammationen som uppstår tros bero på ett överskott av tumörnekrosfaktor (TNF) i kroppen som gör att inflammation och smärta förekommer utan någon direkt anledning. Ungefär 0,5% av befolkningen har AS och det är mer vanligt att män drabbas. Även barn kan drabbas av AS. Adalimumab är en humaniserad monoklonal antikropp och hämmare av cytokinet TNF. Hämmas TNF minskar inflammationen och smärtan i kroppen och progressionen av AS begränsas. Adalimumab ges subkutant via injektion i dosen 40 mg varannan vecka. Syftet med detta litteraturarbete var att undersöka huruvida adalimumab är ett effektivt och säkert läkemedel att använda vid behandling av AS. Artiklarna som undersökts i detta arbete hittades via sökningar i databasen Pubmed och då användes sökorden ”ankylosing spondylitis adalimumab” och ”ankylosing spondylitis adalimumab safety”. Utav resultaten som erhölls från de fem studierna kan det konstateras att adalimumab har god effekt vid behandling av AS jämfört med placebo. De allra flesta värdena som sågs var statistiskt signifikanta. Liknande biverkningar såg från alla studier men de som förekom var av mild grad.

Slutsatsen av detta litteraturarbete är att adalimumab är ett effektivt läkemedel att använda vid behandling av AS. Det minskar symtomen och bromsar upp progressionen av AS. Adalimumab är även ett säkert läkemedel då de vanligaste biverkningarna som förekommer är av mild grad.

Abstract [en]

Ankylosing spondylitis (AS) is chronic inflammatory disease that affects the axial skeleton causing pain and stiffness. The inflammation occurs due to an excess of tumor necrosis factor (TNF) in the body which causes an inflammation without any direct cause. Approximately 0.5% of the population has AS and it´s more common that men suffer from this disease. Children can also be affected by this disease. Adalimumab is a humanized monoclonal antibody and inhibitor of the TNF cytokine. If TNF is inhibited the inflammation and the pain in the body will be reduced and the progression of AS will be limited. Adalimumab is given subcutaneously via injection at a dose of 40 mg every other week. 

The intention with this literature work was to investigate whether adalimumab is an effective and safe drug to use in the treatment of AS. The articles examined in this work were found through searches in the database Pubmed where the words “ankylosing spondylitis adalimumab” were used. This resulted in 32 articles and four of them were selected. Since the four articles found during the first search were very similar, the searchword “safety” was added to broaden the information about adalimumab and look more at side effects adalimumab might possibly give. By adding “safety” the fifth article was found.

The results from these five articles in this literature work shows that adalimumab has god effect in the treatment of AS compared with placebo. A majority of the values seen was statistically significant. Similar side effects were seen from all studies but the reported side effects were mild.

The conclusion of this literature study is that adalimumab is an effective drug to use in the treatment of AS. It reduces the symptoms and slows the progression of AS. Adalimumab is also a safe drug since the most common side effects that occurs are mild.

Place, publisher, year, edition, pages
2019. , p. 28
Keywords [sv]
Akyloserande spondylit, adalimumab
National Category
Medical and Health Sciences
Identifiers
URN: urn:nbn:se:lnu:diva-82384OAI: oai:DiVA.org:lnu-82384DiVA, id: diva2:1312983
Subject / course
Pharmacy
Educational program
Bachelor of Science Programme in Pharmacy, 180 credits
Supervisors
Examiners
Available from: 2019-05-02 Created: 2019-05-01 Last updated: 2019-05-02Bibliographically approved

Open Access in DiVA

fulltext(686 kB)70 downloads
File information
File name FULLTEXT01.pdfFile size 686 kBChecksum SHA-512
8a00f02e0080596eaf02305b682791e2917aa4f13fb409416655b957c64590137a7d2c37a2d5aef844d87d051b723d6bff89c1d3a0edecc4e9d757982f0692b1
Type fulltextMimetype application/pdf

By organisation
Department of Chemistry and Biomedical Sciences
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
Total: 70 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

urn-nbn

Altmetric score

urn-nbn
Total: 33 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf